

### SECTION-1: Identification of the substance / mixture and the company / undertaking

<b>Catalogue Number</b>	CS-ED-42358
<b>Product Name</b>	Isavuconazonium
<b>CAS No.</b>	742049-41-8
<b>Category</b>	API
<b>Synonyms</b>	BAL 8557-000
<b>Brand</b>	Clearsynth Labs Ltd.
<b>Identified uses</b>	Laboratory Chemicals
<b>Uses advised against</b>	Not available
<b>Company</b>	Clearsynth Labs Ltd. Mumbai, India
<b>Emergency Phone #</b>	+91-22-245045900
<b>REACH No.</b>	Not available

### SECTION 2: Hazards identification

**Disclaimer:** This is sample MSDS. Please email [sales@clearsynth.com](mailto:sales@clearsynth.com) for more details.

#### 2.1 Classification of the substance or mixture-Regulation (EC) No 1272/2008:

Not available

#### 2.2 Label Elements

**Signal Word:** Not available

Not available

#### Hazard Statement(s)

Code	Statement
Not available	Not available

#### Precautionary Statement(s)

Code	Statement
Not available	Not available

### SECTION 3: Composition / information on ingredients

#### 3.1 Substance

Component : Isavuconazonium  
CAS Number : 742049-41-8  
Molecular Formula : C<sub>35</sub>H<sub>35</sub>F<sub>2</sub>N<sub>8</sub>O<sub>5</sub>S<sup>+</sup>  
Molecular Weight : 717.76  
Parent Chemical : Isavuconazonium  
Synonyms : BAL 8557-000  
Concentration : Not available

### SECTION 4: First aid measures

#### SECTION 4: First-aid measures

##### 4.1 Description of first aid measures

- General advice: Seek medical attention if symptoms occur or persist. Show this SDS to the physician.
- Inhalation: Move person to fresh air. If breathing is difficult, seek medical attention.
- Skin contact: Wash with soap and water. Remove contaminated clothing and wash before reuse.
- Eye contact: Rinse cautiously with water for several minutes. Remove contact lenses if present and easy to do. Continue rinsing. Get medical attention if irritation persists.
- Ingestion: Rinse mouth. Do not induce vomiting unless directed by medical personnel. Seek medical attention.

##### 4.2 Most important symptoms and effects, both acute and delayed

- Not available.

##### 4.3 Indication of any immediate medical attention and special treatment needed

- Treat symptomatically. No data available.

### SECTION 5: Firefighting measures

#### SECTION 5: Fire-fighting measures

##### 5.1 Extinguishing media

- Suitable extinguishing media: Use extinguishing measures appropriate to surrounding fire (e.g., water spray, alcohol-resistant foam, dry chemical, carbon dioxide).
- Unsuitable extinguishing media: Not available.

##### 5.2 Special hazards arising from the substance or mixture

- Specific hazards: No data available.
- Hazardous combustion products: Not available.

##### 5.3 Advice for firefighters

- Wear self-contained breathing apparatus (SCBA) and full protective gear.
- Cool containers with water spray if exposed to fire.
- Prevent fire-fighting water from entering drains or waterways.

### SECTION 6: Accidental release measures

#### SECTION 6: Accidental release measures

##### 6.1 Personal precautions, protective equipment and emergency procedures

- Avoid breathing dust. Avoid contact with skin and eyes.

- Use appropriate personal protective equipment (see Section 8).
- Ensure adequate ventilation.

#### 6.2 Environmental precautions

- Avoid release to the environment. Prevent entry into drains, surface water, or soil.

#### 6.3 Methods and material for containment and cleaning up

- Avoid generating dust.
- Collect spilled material using suitable methods (e.g., carefully sweep or use HEPA-filtered vacuum).
- Place in a suitable, labeled container for disposal.
- Clean contaminated area with water and detergent as appropriate.

#### 6.4 Reference to other sections

- See Section 8 for personal protective equipment and Section 13 for disposal considerations.

### SECTION-7: Handling and storage

#### SECTION 7: Handling and storage

##### 7.1 Precautions for safe handling

- Handle in accordance with good industrial hygiene and safety practice.
- Avoid formation of dust and aerosols.
- Avoid contact with skin, eyes, and clothing.
- Do not breathe dust.
- Wash hands thoroughly after handling.

##### 7.2 Conditions for safe storage, including any incompatibilities

- Store in a tightly closed container.
- Store in a cool, dry, well-ventilated place.
- Protect from moisture.
- Incompatible materials: Not available.

##### 7.3 Specific end use(s)

- API / laboratory or industrial use. Not for food, drug, or household use. Specific uses not available.

### SECTION 8: Exposure controls / personal protection

#### SECTION 8: Exposure controls/personal protection

##### 8.1 Control parameters

- Occupational exposure limits: Not available.
- Biological limit values: Not available.

##### 8.2 Exposure controls

- Engineering controls: Use local exhaust ventilation or other engineering controls to maintain airborne levels below applicable exposure limits (if established). Use in a fume hood where dust may be generated.
- Personal protective equipment (PPE):
  - Eye/face protection: Safety glasses with side shields or chemical goggles.
  - Skin protection: Protective gloves (material not available). Wear protective clothing.
  - Respiratory protection: If dust or aerosols are generated and ventilation is inadequate, use a suitable particulate respirator in accordance with applicable regulations.

- Hygiene measures: Wash hands after handling. Remove contaminated clothing and wash before reuse.
- Environmental exposure controls: Avoid release to the environment.

## SECTION 9: Physical and chemical properties

### 9.1 Information on basic physical and chemical properties

Test	Result
Appearance	No data available
IR spectrum	No data available
pH	No data available
Solubility	No data available

Property	Value
a) Physical State	No data available
b) Color	No data available
c) Odor	No data available
d) pH	No data available
e) Vapour Pressure	No data available
f) Viscosity	No data available
g) Initial Boiling Point and boiling range	No data available
h) Melting Point / Freezing Point	No data available
i) Auto Ignition Temperature	No data available
j) Flash Point	No data available
k) Explosion Limit, Lower	No data available
l) Explosion Limit, Upper	No data available
m) Decomposition Temperature	No data available
n) Loss on Drying	No data available
o) Relative Density	No data available
p) Solubility (in DMSO)	No data available
q) Oxidizing Properties	No data available

### SECTION 10: Stability and reactivity

#### SECTION 10: Stability and reactivity

##### 10.1 Reactivity

- No data available.

##### 10.2 Chemical stability

- Stable under recommended storage conditions. No data available.

##### 10.3 Possibility of hazardous reactions

- No data available.

##### 10.4 Conditions to avoid

- Avoid dust formation. Avoid exposure to moisture. Other conditions: Not available.

##### 10.5 Incompatible materials

- Not available.

##### 10.6 Hazardous decomposition products

- Not available.

### SECTION 11: Toxicological information

#### 11.1 Information on toxicological effects

- Acute toxicity: Transient elevations in serum aminotransferase levels occur in 1% to 5% of patients on isavuconazonium. These elevations are usually asymptomatic and self-limited, but occasional patients require discontinuation of isavuconazonium because of ALT elevations. Clinically apparent hepatotoxicity has not been reported with isavuconazonium, but it has had limited general use. Other triazoles, such as fluconazole and voriconazole that have been available for more than a decade and have had wide scale use, have been associated with rare instances of clinically apparent liver injury. The injury arises within the first few months of therapy and the pattern of serum enzyme elevations has been variable from cholestatic to hepatocellular. Several cases of acute liver failure attributed to other triazoles have been reported. Immunoallergic features and autoantibodies are uncommon. Recovery upon stopping therapy generally takes 6 to 10 weeks but, in some cases, the time to complete resolution may be prolonged. Likelihood score: E\* (unproven but suspected cause of clinically apparent liver injury).

- Skin corrosion/irritation: No data available.
- Serious eye damage/eye irritation: No data available.
- Respiratory or skin sensitization: No data available.
- Germ cell mutagenicity: No data available.
- Carcinogenicity: No data available.
- Reproductive toxicity: No data available.
- STOT-single exposure: No data available.
- STOT-repeated exposure: No data available.
- Aspiration hazard: No data available.

#### Likely routes of exposure

- No data available.

#### Symptoms related to the physical, chemical and toxicological characteristics

- Transient elevations in serum aminotransferase levels occur in 1% to 5% of patients on isavuconazonium. These elevations are usually asymptomatic and self-limited, but occasional patients require discontinuation of

isavuconazonium because of ALT elevations. Clinically apparent hepatotoxicity has not been reported with isavuconazonium, but it has had limited general use. Other triazoles, such as fluconazole and voriconazole that have been available for more than a decade and have had wide scale use, have been associated with rare instances of clinically apparent liver injury. The injury arises within the first few months of therapy and the pattern of serum enzyme elevations has been variable from cholestatic to hepatocellular. Several cases of acute liver failure attributed to other triazoles have been reported. Immunoallergic features and autoantibodies are uncommon. Recovery upon stopping therapy generally takes 6 to 10 weeks but, in some cases, the time to complete resolution may be prolonged. Likelihood score: E\* (unproven but suspected cause of clinically apparent liver injury).

### SECTION 12: Ecological information

#### SECTION 12: Ecological information

##### 12.1 Toxicity

- Not available.

##### 12.2 Persistence and degradability

- Not available.

##### 12.3 Bioaccumulative potential

- Not available.

##### 12.4 Mobility in soil

- Not available.

##### 12.5 Results of PBT and vPvB assessment

- Not available.

##### 12.6 Endocrine disrupting properties

- Not available.

##### 12.7 Other adverse effects

- Not available.

### SECTION 13: Disposal considerations

#### SECTION 13: Disposal considerations

##### 13.1 Waste treatment methods

- Dispose of contents/container in accordance with local/regional/national/international regulations.
- Do not discharge to drains.
- Recommended disposal method: Not available.
- Contaminated packaging: Dispose of as unused product or according to local requirements.

### SECTION 14: Transport information

#### SECTION 14: Transport information

- UN number: Not available.
- UN proper shipping name: Not available.
- Transport hazard class(es): Not available.

- Packing group: Not available.
- Environmental hazards: Not available.
- Special precautions for user: Not available.
- Transport in bulk according to IMO instruments: Not available.

### SECTION 15: Regulatory information

#### SECTION 15: Regulatory information

##### 15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

- Regulatory status (GHS/CLP/OSHA/WHMIS/TSCA/REACH, etc.): Not available.

##### 15.2 Chemical safety assessment

- Not available.

### SECTION 16: Other information

#### SECTION 16: Other information

- Product name: Isavuconazonium
- Catalog No.: CS-ED-42358
- CAS No.: 742049-41-8
- Synonyms: BAL 8557-000
- Supplier: Clearsynth Labs Ltd., Mumbai, India
- Emergency phone: +91-22-245045900

#### Disclaimer

- The information provided is believed to be accurate based on available data; however, no warranty is expressed or implied. Users must determine suitability for their particular purpose and comply with applicable regulations.

#### Revision information

- Revision date: Not available.
- Version: Not available.

### DISCLAIMER

This MSDS is system-generated. Please verify and confirm all data, statements, and values with the Support Team before use or distribution.